Tuesday, 3 May 2005. Melbourne, Australia - Meditech Research Ltd (ASX: MTR), a biotechnology company developing new cancer therapies, today announced that its Chief Executive Officer, Dr Ian Nisbet, will present at the second annual Rodman & Renshaw Global Healthcare Conference on May 5th, 2005 in Paris, France.

More than 200 international emerging growth biotechnology companies will present at the conference on various topics ranging from oncology and cardiovascular disease to infectious disease and medical device technology. The conference will be attended by institutional investors from a number of countries, venture capitalists, industry leaders and global experts from the scientific and medical community.

"Presentation of Meditech's business plans and product data to both European and US investors is part of our commitment to raise the Company's profile and increase the awareness of our technology," said Dr Nisbet. "This is a great opportunity for Meditech to showcase itself to a global audience at a premier healthcare investment conference."

Last year's conference attracted more than 800 participants.

Rodman & Renshaw LLC is a privately held, full-service investment bank, working with emerging growth companies in the life science and technology sectors. During the past two years, Rodman & Renshaw completed more than 60 financing transactions, totaling over US$1 billion.

For more information:

Dr Ian Nisbet, CEO

Phone: (03) 9296 2027 or Mobile: 0431 709 121

Meditech is an Australian biotechnology company focused on developing and commercialising drugs that improve the health and quality of life of patients with cancer and other chronic diseases. The company has internationally recognised expertise in carbohydrate-based therapies, particularly products based upon the glycosaminoglycan, hyaluronic acid. Building on this expertise, Meditech has created its patented HyACT(TM) (Hyaluronic Acid Chemotransport Technology) platform which it is applying to the development of improved formulations of cancer drugs. The lead product from the HyACT(TM) platform is HyCAMP(TM). In addition to HyCAMP(TM), Meditech has taken the anti-cancer products HyDOX(TM) (doxorubicin and hyaluronic acid) and HyFIVE(TM) (5-fluorouracil and hyaluronic acid) into clinical testing.

About HyCAMP(TM)

HyCAMP(TM) is Meditech's proprietary formulation of irinotecan (CamptosarR) with hyaluronic acid, which is currently in Phase II clinical testing in metastatic colorectal cancer patients. It has previously been tested in a 12-patient, uncontrolled Phase I study, the interim results of which were presented at the 29th Congress of the European Society for Medical Oncology

(ESMO) in October 2004. Although the number of patients in the Phase I study was not sufficient to draw any firm conclusions, treatment with HyCAMP(TM) showed a trend towards improved safety with maintained efficacy.